RLMD — RELMADA THERAPEUTICS, INC.

—
Nasdaq · Health Care · Pharmaceuticals · CIK 1553643 ·
Last close
$3.01
Market Cap
$321.15M
52W High
$8.00
52W Low
$2.98
ADV30
1,666,920
Next earnings
2026-11-12
Relmada Therapeutics, Inc. operates as a clinical-stage biotechnology company in the United States. The company focuses on the development of NDV-01, a controlled-release intravesical formulation of gemcitabine and docetaxel, which is in Phase 2 clinical trial for patients with aggressive forms of non-muscle invasive bladder cancer; and Sepranolone, a neurosteroid epimer of allopregnanolone, which is Phase 2b-ready for the potential treatment of prader-willi syndrome, tourette syndrome, excessive tremor, and other diseases related to excessive GABAergic activity. The company has an agreement with Asarina Pharma AB and Trigone. Relmada Therapeutics, Inc. was founded in 2004 and is headquartered in Coral Gables, Florida.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 0 — -13,096,423 -13,862,188 205,296,615 5,720,325 11,559,554
Jun 2026 0 — -15,011,027 -12,914,185 219,059,177 11,334,370 12,500,854
Mar 2026 0 — -19,461,754 -19,051,956 235,362,794 9,776,400 16,630,217
Dec 2025 0 — -20,333,112 -19,867,760 94,003,471 3,496,540 7,491,458

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-45,992,000
Investing CF
$-187,818,172
Financing CF
$243,791,191
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.93
As of
2026-11-15

Balance + Analyst (yfinance extras)

Retained Earnings
$-730,233,339
Inventory
—
Receivables
$10,912
ST Investments
$206,396,805
EBIT TTM
$-65,133,239
Pretax Income TTM
$-61,925,397
Interest Exp TTM
—
Analysts
4

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 0 -59,100,200 -57,385,163 94,003,471 7,491,458 86,512,013 -45,786,988
Dec 2024 0 -83,891,036 -79,979,354 45,817,818 10,295,857 35,521,961 -51,755,798
Dec 2023 0 -103,702,293 -98,791,746 97,552,042 12,194,800 85,357,242 -51,659,206
Dec 2022 0 -161,249,076 -157,043,823 152,905,179 12,468,877 140,436,302 -103,801,617

TTM Snapshot

Revenues TTM
$3,895,400
NetIncome TTM
$-61,925,397
OpCashFlow TTM
—
Assets (Latest)
$219,059,177
Forward EPS
$-0.41

Max Pain — expiry 2027-12-17 (volume-derived — Yahoo OI feed degraded)

max pain strike: $2.50 · spot: $2.85 · call volume: 652 · put volume: 2

Peers — same industry

TickerNameMarket CapLastDaily %
AVIR Atea Pharmaceuticals, Inc. $318.00M $3.96 —
LRMR Larimar Therapeutics, Inc. $310.61M $2.99 —
LYEL Lyell Immunopharma, Inc. $336.08M $13.67 —
CTNM Contineum Therapeutics, Inc. $337.62M $9.55 —
INO INOVIO PHARMACEUTICALS, INC. $305.31M $1.63 —

News headlines (Yahoo Finance, 1h cache)

Relmada Therapeutics Appoints Uro-Oncology Leader Jørn Skibsted Jakobsen, MD, PhD, as Chief Development Officer
2026-11-16 07:00 · Yahoo
Relmada Therapeutics, Inc. Q3 2026 Earnings Call Summary
2026-11-13 13:30 · Yahoo
Relmada (RLMD) Q3 2026 Earnings Call Transcript
2026-11-13 05:43 · Yahoo
What Relmada Therapeutics (RLMD) Said on Its Q3 Earnings Call
2026-11-13 05:14 · Yahoo
Relmada Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update
2026-11-12 21:05 · Yahoo
Relmada Therapeutics to Participate at the Jefferies Global Healthcare Conference in London
2026-11-04 12:00 · Yahoo
Relmada Therapeutics to Report Third Quarter 2026 Financial Results on Thursday, November 12, 2026
2026-11-03 12:00 · Yahoo
After Plunging 18.5% in 4 Weeks, Here's Why the Trend Might Reverse for Relmada Therapeutics (RLMD)
2026-08-31 13:35 · Yahoo
Here's Why Relmada Therapeutics (RLMD) Is a Great 'Buy the Bottom' Stock Now
2026-08-25 13:55 · Yahoo
Down 29.6% in 4 Weeks, Here's Why Relmada Therapeutics (RLMD) Looks Ripe for a Turnaround
2026-08-11 13:35 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.